Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility | MicrobiomeTrials← Back to trialsNCT04244877
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
WITHDRAWNPHASE3INTERVENTIONAL
Trial Details
Start: 2021-09-15Est. Completion: 2023-05-01
Enrollment target: 0 participants Other microbiome trials you might be interested in
Chronic Hepatitis B Infection
France is a low-endemicity country for hepatitis B virus (HBV) infection. In 2016, the prevalence of chronic HBV infecti…
Créteil, FranceEst. completion Sep 1, 2029
NASH With FibrosisMASH With Fibrosis
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subje…
Birmingham, United StatesEst. completion Feb 2033
Recruiting
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiven…
Ancona, ItalyEst. completion Oct 31, 2028